Search

Your search keyword '"Avvisati, G."' showing total 24 results
Start Over Author "Avvisati, G." Publisher elsevier bv
24 results on '"Avvisati, G."'

1. Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?

Author

Annibali, O., primary, Petrucci, M.T., additional, Santini, D., additional, Bongarzoni, V., additional, Russano, M., additional, Pisani, F., additional, Venditti, O., additional, Pantano, F., additional, Rago, A., additional, Siniscalchi, A., additional, Cerchiara, E., additional, Franceschini, L., additional, De Rosa, L., additional, Mariani, M., additional, Andriani, S, additional, Cudillo, L., additional, Garcia, M., additional, Cantonetti, M., additional, Mohamed, S., additional, Anaclerico, B., additional, Caravita, T., additional, Stocchi, F., additional, Cimino, G., additional, Gumenyuk, S., additional, Vozella, F., additional, and Avvisati, G., additional

Published
2021
Full Text
View/download PDF

4. Acute promyelocytic leukemia: Clinical and morphologic features and prognostic factors

Author

Avvisati, G, LO COCO, F, and Mandelli, F

Subjects
Promyelocytic, Leukemia, Leukemia, Promyelocytic, Acute, Humans, Antineoplastic Agents, Prognosis, Tretinoin, Hematology, Acute, Settore MED/15 - Malattie del Sangue
Abstract

The most impressive clinical feature of acute promyelocytic leukemia (APL) at diagnosis is the presence in 80% to 90% of patients of a severe hemorrhagic syndrome. Recent data favor a fibrinolytic/proteolytic process rather than a disseminated intravascular coagulation as the mechanism mainly responsible for the hemorrhagic diathesis in APL. Morphologically, two main cytologic variants have been Identified: the classical hypergranular APL (M3), which represents the great majority of all APL, and the microgranular variant (M3v), which accounts for about 15% to 20% of all APL. A rare basophilic variant has also been described. With regard to prognosis, it has markedly changed from that of a rapidly fatal acute leukemia to that of a highly curable disease. This revolutionary progress was mainly due to the introduction during the 1990s of all-trans retinoic acid (ATRA) for the treatment of this disease. After the introduction of ATRA, in addition to clinical features such as hyperleukocytosis (white blood cell count10 x 10(9)/L) or thrombocytopenia (platelet count10 x 10(3)/L) at presentation, immunophenotype markers and polymerase chain reaction status for promyelocytic leukemia/retinoic acid receptor-alpha during follow-up also had an impact on prognosis.

Published
2001
Full Text
View/download PDF

5. Alkaline Phosphatase (ALP) Levels in Multiple Myeloma (MM) And Cancer With Bone Lesions : Is There any Difference?

Author

Annibali, O., primary, Petrucci, M.T., additional, Santini, D., additional, Mariani, M., additional, Pisani, F., additional, Bongarzoni, V., additional, Venditti, O., additional, Rago, A., additional, Cerchiara, E., additional, Fiorini, A., additional, Franceschini, L., additional, Vallone, M.L., additional, Felici, S., additional, Russano, M., additional, Pantano, F., additional, and Avvisati, G., additional

Published
2015
Full Text
View/download PDF

6. The Role of Interferon-α in the Management of Myelomatosis

Author

Mandelli F and Avvisati G

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Salvage treatment, Alpha interferon, Hematology, Immunotherapy, medicine.disease, Cytokine, Internal medicine, Immunopathology, Interferon α, Immunology, Medicine, business, Multiple myeloma, Interferon alfa, medicine.drug
Abstract

This article reviews the therapeutic efficacy of α-interferon (α-IFN) in the management of myelomatosis. Four major therapeutic uses of α-IFN in myelomatosis are reviewed: 1) The use of α-IFN alone as induction treatment of previously untreated multiple myeloma patients; 2) the association of α-IFN to conventional induction therapies; 3) the use of α-IFN as salvage treatment for multiple myeloma; and 4) the use of α-IFN as maintenance treatment for multiple myeloma patients responding to conventional chemotherapies. Published data indicate that a better control of multiple myeloma is obtained by combining (during the induction treatment) α-IFN to conventional chemotherapies and adding, once a plateau phase has been achieved, a continuous maintenance treatment of α-IFN.

Published
1992
Full Text
View/download PDF

20. Epidemiology of acute promyelocytic leukemia in Italy

Author

Avvisati, G., primary, Mele, A., additional, Stazi, M.A., additional, Vegna, M.L., additional, Pasquini, P., additional, Mandelli, F., additional, Rotoli, B., additional, De Rosa, G., additional, Papa, G., additional, Venditti, A., additional, Citarrella, P., additional, Tambone Reyes, M., additional, Ascari, E., additional, Invernizzi, R., additional, Cajozzo, A., additional, Musso, M., additional, Alberti, A., additional, Peta, A., additional, Rossi Ferrini, P., additional, Leoni, F., additional, Caronia, F., additional, Mirto, S., additional, Nobile, F., additional, Iacopino, P., additional, Resegotti, L., additional, Allione, B., additional, Monfardini, S., additional, Zagonel, V., additional, Liso, V., additional, Specchia, G., additional, Tura, S., additional, Visani, G., additional, Broccia, G., additional, Deplano, W., additional, Ricciuti, F., additional, Pizzuti, M., additional, Longinotti, M., additional, Bonfigli, S., additional, De Laurenzi, A., additional, Pacilli, L., additional, Deriu, L., additional, Chierichini, A., additional, Bizzi, B., additional, Leone, G., additional, De Biasi, R., additional, Miraglia, E., additional, Bruzzese, L., additional, and Abbadessa, A., additional

Published
1991
Full Text
View/download PDF

24. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Author

Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Mario Boccadoro, Simona Barbato, Patrizia Tosi, Franco Narni, Vittorio Montefusco, Nicoletta Testoni, Antonio Spadano, Carolina Terragna, Norbert Pescosta, Giulia Marzocchi, Claudia Cellini, Piero Galieni, Sonia Ronconi, Marco Gobbi, Lucio Catalano, Antonio Lazzaro, Giovanni De Sabbata, Clotilde Cangialosi, Fabrizio Ciambelli, Pellegrino Musto, Francesca Elice, Michele Cavo, Renato Fanin, Roberto Foa', Alessandro Rambaldi, Giuseppe Rossi, Pietro Leoni, Paolo Corradini, Giuseppe Torelli, Giuseppe Fioritoni, Sergio Cortelazzo, Giorgio Lambertenghi Deliliers, Giorgio La Nasa, Alfonso Zaccaria, Paolo De Fabritiis, Nicola Cascavilla, Alberto Bosi, Gianpietro Semenzato, Luigi Gugliotta, Filippo Gherlinzoni, Emanuele Angelucci, Massimo Fabrizio Martelli, Maria Concetta Petti, Giuseppe Leone, Angelo Michele Carella, Fabio Ciceri, Armando Santoro, Felicetto Ferrara, Francesco Nobile, Alfonso Maria D'Arco, Alessandro Levis, Luciano Guardigni, Andrea Gallamini, Pier Paolo Fattori, Sergio Morandi, Dino Amadori, Bruno Rotoli, Salvatore Mirto, Giorgio Paladini, Ruggero Mozzana, Graziella Pinotti, Francesco Rodeghiero, Nicola Cantore, Vincenzo Pavone, Enrico Maria Pogliani, Anna Marina Liberati, Ignazio Majolino, Sergio Amadori, Francesco Lauria, Massimo Aglietta, Giovanni Quarta, Sergio Storti, Fortunato Morabito, Silvana Franca Capalbo, Alessandro Massimo Gianni, Vincenzo Mettivier, Vittorio Rizzoli, Carlo Bernasconi, Giuseppe Visani, Michele Pizzuti, Giacinto La Verde, Giuseppe Avvisati, Maurizio Longinotti, Eugenio Gallo, Franco Dammacco, Domenico Russo, Andrea Bacigalupo, Caterina Musolino, Tacchetti P., Pantani L., Patriarca F., Petrucci M.T., Zamagni E., Dozza L., Galli M., Di Raimondo F., Crippa C., Boccadoro M., Barbato S., Tosi P., Narni F., Montefusco V., Testoni N., Spadano A., Terragna C., Pescosta N., Marzocchi G., Cellini C., Galieni P., Ronconi S., Gobbi M., Catalano L., Lazzaro A., De Sabbata G., Cangialosi C., Ciambelli F., Musto P., Elice F., Cavo M., Fanin R., Foa' R., Rambaldi A., Rossi G., Leoni P., Corradini P., Torelli G., Fioritoni G., Cortelazzo S., Lambertenghi Deliliers G., La Nasa G., Zaccaria A., De Fabritiis P., Cascavilla N., Bosi A., Semenzato G., Gugliotta L., Gherlinzoni F., Angelucci E., Martelli M.F., Petti M.C., Leone G., Carella A.M., Ciceri F., Santoro A., Ferrara F., Nobile F., D'Arco A.M., Levis A., Guardigni L., Gallamini A., Fattori P.P., Morandi S., Amadori D., Rotoli B., Mirto S., Paladini G., Mozzana R., Pinotti G., Rodeghiero F., Cantore N., Pavone V., Pogliani E.M., Liberati A.M., Majolino I., Amadori S., Lauria F., Aglietta M., Quarta G., Storti S., Morabito F., Capalbo S.F., Gianni A.M., Mettivier V., Rizzoli V., Bernasconi C., Visani G., Pizzuti M., La Verde G., Avvisati G., Longinotti M., Gallo E., Dammacco F., Russo D., Bacigalupo A., and Musolino C.

Subjects
Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Adolescent, Phases of clinical research, Transplantation, Autologous, Dexamethasone, Bortezomib, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, GIMEMA-MMY-3006 trial, bortezomib, thalidomide, dexamethasone, VTD, double autologous haematopoietic stem-cell transplantation, multiple myeloma, Multiple myeloma, Aged, Intention-to-treat analysis, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, medicine.disease, Thalidomide, Transplantation, Regimen, 030220 oncology & carcinogenesis, Female, Multiple Myeloma, business, Follow-Up Studies, 030215 immunology, medicine.drug
Abstract

Background: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous haematopoietic stem-cell transplantation (HSCT) for newly diagnosed multiple myeloma, showed the superiority of the triplet regimen over the doublet in terms of increased complete response rate and improved progression-free survival. We report the results from the final analysis of the study. Methods: In this randomised, open-label, phase 3 study, patients aged 18–65 years with previously untreated symptomatic multiple myeloma and a Karnofsky Performance Status of 60% or higher were enrolled at 73 centres in Italy. Patients were randomised (1:1) by a web-based system to receive three 21-day cycles of thalidomide (100 mg daily orally for the first 14 days and 200 mg daily thereafter) plus dexamethasone (total 320 mg per cycle; 40 mg on days 1–2, 4–5, 8–9, and 11–12 in the VTD regimen, and 40 mg on days 1–4 and 9–12 in the TD regimen), either alone (TD group) or with bortezomib (1·3 mg/m2 intravenously on days 1, 4, 8, and 11; VTD group). After double autologous HSCT, patients received two 35-day cycles of either the VTD or TD regimen, according to random assignment, as consolidation therapy. The primary outcome was the rate of complete response and near complete response after induction (already reported). In this updated analysis we assessed long-term progression-free survival and overall survival (secondary endpoints of the study) with an extended 10-year median follow-up, and analysed the variables influencing survival. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, NCT01134484. Findings: Between May 10, 2006, and April 30, 2008, 480 patients were enrolled and randomly assigned to receive VTD (241 patients) or TD (239 patients). Six patients withdrew consent before start of treatment. 236 (99 [42%] women) in the VTD group and 238 (102 [43%] women) in the TD group were included in the intention-to-treat analysis. The data cutoff date for this analysis was May 31, 2018. Median follow-up for surviving patients was 124·1 months (IQR 117·2–131·7). The 10-year progression-free survival estimate for patients in the VTD group was 34% (95% CI 28–41) compared with 17% (13–23) for the TD group (hazard ratio [HR] 0·62 [95% CI 0·50–0·77]; p

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results